Pricing Log in Create free account

Adaptimmune Therapeutics PLC (ADAPY) vs Radiopharm Theranostics Limited - Sponsored ADR (RADX)

Adaptimmune Therapeutics PLC and Radiopharm Theranostics Limited - Sponsored ADR are both Biotechnology companies. Adaptimmune Therapeutics PLC and Radiopharm Theranostics Limited - Sponsored ADR are of similar size ($14.6M and $14.0M). Across the 7 metrics below, Radiopharm Theranostics Limited - Sponsored ADR leads on 4 and Adaptimmune Therapeutics PLC on 3.

Valuation

Metric ADAPY RADX Biotechnology median
P/E n/m — 10.60
P/S 0.08 — 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 0.08 n/m 9.02
Earnings yield (3,250.00%) — (32.88%)
Free cash flow yield (3,648.13%) 0.00% (23.13%)

Profitability

Metric ADAPY RADX Biotechnology median
Gross margin 94.81% — 68.51%
Operating margin (427.75%) — 0.00%
Net margin (262.46%) — 0.00%
Free cash flow margin (294.49%) 0.00% 0.00%
Return on equity (1,349.52%) 0.00% (51.96%)
Return on assets 0.00% 0.00% (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ADAPY RADX Biotechnology median
Revenue growth (TTM) (53.99%) — 6.76%
EPS growth (last fiscal year) 142.86% (1.97%) 29.88%
Revenue growth, 5-year CAGR 8.40% — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ADAPY RADX Biotechnology median
Debt to equity (0.36) 0.00 0.00
Current ratio 1.52 1.16 4.97
Net debt to EBITDA 0.47 0.08 1.01

Dividend

Metric ADAPY RADX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ADAPY RADX Biotechnology median
Market cap 14.55m 13.96m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack